Generated by AI
PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders. Its current portfolio includes treatments for conditions such as Duchenne muscular dystrophy, phenylketonuria, and aromatic L-amino acid decarboxylase deficiency, along with other rare neurological and metabolic diseases. The company also works on gene therapy and small-molecule programs designed to address serious unmet medical needs. PTC Therapeutics serves children and adults in the United States and international markets, and its commercial offerings are supported by a research and development pipeline aimed at expanding its rare disease franchise. Headquartered in Warren, New Jersey, PTC Therapeutics plays a specialized role in the biopharmaceutical market by concentrating on niche therapies for complex, underserved patient populations.
Website500 Warren Corporate Center Drive
Warren, NJ, 07059
United States
The latest articles about PTCT.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
Summary of May 8's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Summary of Sep 18's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Investors talking about PTCT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.